Dr. Reddy's Laboratories Limited RDY
14.30 USD +0.17 (+1.20%)
At closeNov 3, 2026, 4:03 PM EST
14.02 -0.28 -1.96%
After hours · Nov 3, 4:03 PM ET
14.23 Day range 14.42
11.36 52-week range 15.67
- YTD
- +1.85%
- 1 year
- +6.64%
Analyst view
Consensus: buy
Buy
Price target (mean) 14.34 +0.3% upside
Now 14.30
- Target (low)
- 12.53
- Target (mean)
- 14.34
- Target (high)
- 15.73
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 90.49B | +3.7% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 90.86B | +20.9% | 0 |
| Current year | 46.22 | 43.73 – 48.70 | 55.39 | -16.6% | 351.28B | +4.6% | 2 |
| Next year | 62.49 | 59.86 – 65.12 | 46.22 | +35.2% | 393.17B | +11.9% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 2026 | Citigroup | Upgrade | Sell | Buy |
| Jun 5, 2025 | HSBC | Upgrade | Hold | Buy |
| Nov 6, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jul 30, 2024 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jan 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jun 1, 2023 | Barclays | Maintained | Overweight | Overweight |
| Oct 31, 2022 | Barclays | Maintained | — | Overweight |
| Oct 25, 2022 | Barclays | Maintained | — | Overweight |
| Sep 12, 2022 | Barclays | Maintained | — | Overweight |
| Jul 25, 2022 | Barclays | Maintained | — | Overweight |
| May 24, 2022 | Barclays | Maintained | — | Overweight |
| Nov 1, 2021 | Barclays | Maintained | — | Overweight |
| Feb 2, 2021 | Barclays | Upgrade | Equal-Weight | Overweight |
| Jan 28, 2020 | CLSA | Downgrade | Buy | Outperform |
| Jan 9, 2020 | Citigroup | Upgrade | Sell | Buy |
| Nov 4, 2019 | B of A Securities | Downgrade | Buy | Neutral |
| Sep 4, 2019 | Credit Suisse | Upgrade | Underperform | Outperform |
| Jun 11, 2019 | Barclays | Initiated | — | Equal-Weight |
| May 20, 2019 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Nov 1, 2017 | Jefferies | Maintained | — | Underperform |
| Sep 21, 2017 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Jul 27, 2016 | HSBC | Downgrade | Hold | Reduce |
| Jul 27, 2016 | Jefferies | Downgrade | Hold | Underperform |
| Jul 26, 2016 | Credit Suisse | Downgrade | Neutral | Underweight |
| May 2, 2016 | Goldman Sachs | Initiated | — | Neutral |
| Feb 10, 2016 | CLSA | Upgrade | Underperform | Buy |
| Dec 2, 2015 | Deutsche Bank | Initiated | — | Sell |
| Feb 15, 2013 | B of A Securities | Downgrade | Buy | Neutral |
| Dec 12, 2012 | Credit Suisse | Upgrade | Neutral | Outperform |